Drug Trial Radar · NCT00193635
Pilot Study of Mycophenolate Mofetil in Congenital Uropathies
Last checked: Nov 20, 2026Latest source record: Oct 19, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Mar 2002
Primary completion
Not stated
Study completion Aug 2007
Sponsor
- Lead sponsor
- Northwell HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hoffmann-La Roche; University of Medicine and Dentistry of New Jersey; New York Presbyterian Hospital
- First posted
- Sep 19, 2005
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 3 years, up to 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Congenital or hereditary structural anomalies of the genitourinary tract account for approximately half of all cases of end stage renal disease in the pediatric population. Despite optimal medical management, when the GFR falls below 50 ml/min/1.73 M2, nearly 40% of affected children will require dialysis or a renal transplant within 2 years. At present, there is no specific treatment for patients with congenital uropathies that can retard the progressive loss of kidney function and forestall the need for renal replacement therapy. There is evidence in experimental animals and in patients with chronic renal failure (CRF) that immunoeffector mechanisms are activated within the renal parenchyma. Infiltration of the kidney by macrophages, monocytes, and lymphocytes, activation of renal tubular epithelial cells, and release of pro-inflammatory cytokines result in fibrosis and irreversible organ damage. Mycophenolate mofetil (MMF) is a new immunosuppressive agent that is used to prevent acute rejection in kidney transplant recipients. It attenuates renal damage in the remnant kidney model of CRF in which there is no primary immunological injury. Therefore, this pilot study is designed to test the hypothesis that immunosuppressive treatment with MMF in children with structural causes of CRF will be safely tolerated and that this therapy will retard progressive decline in renal function. Patients with congenital uropathy, 3-16 years of age and with a GFR less than 50 ml/ml/1.73 M2, will be treated with MMF for 24 months. The two primary endpoints are: (1) safety and tolerance of the drug; and (2) need for dialysis or kidney transplantation. It is anticipated that the MMF will be free of significant toxicity and that administration of the drug will reduce the frequency of progression to end stage renal disease from 38% to 19%. Patients will be followed at 3-month intervals and they will undergo serial assessment of proteinuria, estimated GFR and iothalamate clearance, urinary cytokine excretion, urine flow cytometry, and immunologic testing. The significance of this pilot study is that it may provide evidence in support of a randomized, double-blind, placebo-controlled trial of immunological treatment of congenital structural causes of CRF in children
Conditions
- Congenital Urological Abnormalities
Interventions
mycophenolate mofetilDrug
oral drug administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction in GFRTime frame: 24 month treatment period
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Robert Wood Johnson Medical center
New Brunswick, New Jersey
Schneider Children's Hospital
New Hyde Park, New York
Cornell Weill Medical Center
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.